NCT01994668View on ClinicalTrials.gov

Phase 1 Study to Characterize the Safety and Pharmacokinetics of Single Intravenous Dose of Lorazepam in Healthy Japanese Adult Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

February 28, 2014

Study Completion Date

February 28, 2014

Conditions
Healthy
Interventions
DRUG

Lorazepam

A single intravenous administration of 2 mg lorazepam over 1 minute

DRUG

Placebo

A single intravenous administration of 0.9% saline over 1 minute

Trial Locations (1)

Unknown

Pfizer Investigational Site, Hachioji-shi

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT01994668 - Phase 1 Study to Characterize the Safety and Pharmacokinetics of Single Intravenous Dose of Lorazepam in Healthy Japanese Adult Subjects | Biotech Hunter | Biotech Hunter